Aviragen Therapeutics (AVIR) Tops Q2 EPS by 15c
Tweet
Share
E-mailGet Alerts AVIR Hot Sheet
Join SI Premium – FREE
Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.41), $0.15 better than the analyst estimate of ($0.56).
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Active options: NVDA TSLA SPCX MU AAPL INTC CRWV
- Nvidia and Broadcom AI financing deals raise long-term concerns, Wolfe Research comments
- Tutor Perini unit wins $42M construction contract in Saudi Arabia
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
